New Prime Minister Could Usher in a New Era For India

05.19.14 | By

Last week, after an election process that took more than a month to complete with a record 550 million votes cast, the Indian people elected a new Prime Minister in a landslide election that unseated the country’s ruling Congress party.  Narendra Modi and the Bharatiya Janata Party (BJP) won enough seats in the lower house of Parliament to form a government.

Week in Review: Building a Robust Pipeline for Patients

05.09.14 | By

Biopharmaceutical innovators work every day to build a robust pipeline and develop new medicines that help patients cope with some of the most debilitating diseases. This week, we released a new Medicines in Development report on mental health disorders that discussed a number of new approaches being pursued in order to treat these conditions. Currently, an estimated 61.5 million Americans suffer from mental illness, or one in every four U.S.

Prescription Drug Abuse Monitoring Programs Offer Value to States Combating Misuse

05.07.14 | By

Each year at the National Prescription Drug Abuse Summit, discussions take place regarding the latest resources and tools for states, pharmacists, physicians, and law enforcement to use in combating the misuse and abuse of prescription medicines. For PhRMA, ensuring the appropriate use of medicines and preventing fraud and diversion of prescription medicines is of paramount importance.

The Parkinson Story

04.29.14 | By

Parkinson's is chronic and progressive, meaning that symptoms continue and can increase over time. The progression of Parkinson’s disease varies and is different for everyone. No one can predict which symptoms will affect an individual, and the intensity of the symptoms also varies. With April being Parkinson’s Awareness Month part of our efforts include reaching out to the community to hear their Parkinson stories.

Cancer Medicines: Adding Value to the Cost Equation

04.24.14 | By

The questions on cost and value are important, but they miss the opportunity to reach consensus, patient-centered solutions. Read the four places the discussions focused on cost often run amiss:

Reforming 340B

04.16.14 | By

For the last 20 years, the federal 340B has helped biopharmaceutical companies and hospitals partner to share treatments and medicines at a discounted price with those who could not otherwise afford them. The program has helped millions of uninsured and vulnerable patients gain access to the treatments necessary to lead fuller — healthier lives. Unfortunately, the 340B program lacks an effective oversight mechanism to ensure the discounted treatments are reaching their intended recipients.

PhRMA 56th Annual Meeting Spotlights Conversion of Hope into Cures for Patients

04.16.14 | By

Last Friday marked another successful PhRMA Annual Meeting where the biopharmaceutical and patient community, policy makers, academics, and more, came together to discuss challenges and opportunities facing patients today. The Annual Meeting covered an array of topics all centering on the theme of: How we can convert hopes into cures for our nation’s patients.

Hepatitis C Debate Should Focus on Value of Innovative Medicines

04.15.14 | By

As the debate around the cost of Hepatitis C treatment rages on, a Bloomberg article yesterday highlighted other potential Hepatitis C medicines on the horizon and the many benefits they could provide for patients living with this debilitating disease. What’s more, many of the potential new medicines might be able to offer patients fewer unwanted side effects and require less monitoring and follow-up care.

#PhRMA14: Collaborating with Patients to Advance R&D

04.15.14 | By

Collaboration was rightly a focal point of #PhRMA14 because it is incredibly important to developing new medicines. As PhRMA CEO John Castellani said at the meeting, the industry is changing rapidly and we continue to compete by “joining hands…building new strength and breadth…[and] adapting and leading.” One of the most important ways to accomplish this is by incorporating the patient into everything we do. 

Stakeholders Urge Caution in Senate Consideration of Patent Reform

04.07.14 | By

ScientistBiopharmaceutical innovation is not a given.  Strong intellectual property protections are necessary to sustain America’s role as the worldwide leader in biopharmaceutical research and are critical to the biopharmaceutical industry’s ability to make the

Pages

Subscribe to RSS - Opinion